Astellas acquires selected Asian rights to Ironwood's IBS drug
This article was originally published in Scrip
Astellas has paid $30 million up front for exclusive rights in Japan and most other Asian markets to linaclotide, Ironwood Pharmaceuticals' drug for constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context